CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 471 filers reported holding CRISPR THERAPEUTICS AG in Q3 2021. The put-call ratio across all filers is 1.71 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $379,890 | -25.4% | 8,369 | -7.7% | 0.05% | -19.3% |
| Q2 2023 | $509,072 | +30.1% | 9,068 | +4.9% | 0.06% | +29.5% |
| Q1 2023 | $391,169 | +10.4% | 8,648 | -0.8% | 0.04% | +10.0% |
| Q4 2022 | $354,262 | -100.0% | 8,715 | -67.0% | 0.04% | -79.9% |
| Q3 2022 | $1,727,646,000 | +122.1% | 26,437 | +106.6% | 0.20% | +139.8% |
| Q2 2022 | $777,825,000 | +68551.8% | 12,799 | -29.1% | 0.08% | -18.6% |
| Q1 2022 | $1,133,000 | -38.3% | 18,057 | -25.5% | 0.10% | -24.4% |
| Q4 2021 | $1,836,000 | -31.5% | 24,229 | +1.2% | 0.14% | -34.1% |
| Q3 2021 | $2,680,000 | -22.5% | 23,942 | +12.2% | 0.20% | -20.2% |
| Q2 2021 | $3,456,000 | +23.3% | 21,346 | -7.2% | 0.26% | +17.9% |
| Q1 2021 | $2,804,000 | – | 23,009 | – | 0.22% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $32,581,000 | 55.55% |
| NEA Management Company, LLC | 1,590,002 | $103,907,000 | 5.19% |
| ARK Investment Management | 8,237,122 | $538,296,000 | 3.75% |
| Nikko Asset Management Americas, Inc. | 4,262,736 | $277,078,000 | 3.54% |
| CLOUGH CAPITAL PARTNERS L P | 414,767 | $27,105,000 | 2.89% |
| Integral Health Asset Management, LLC | 220,000 | $14,377,000 | 2.79% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,268,000 | 2.48% |
| HC Advisors, LLC | 53,944 | $3,525,000 | 2.43% |
| Green Alpha Advisors, LLC | 27,466 | $1,795,000 | 1.52% |
| EFG Asset Management (North America) Corp. | 84,356 | $5,516,000 | 1.28% |